Description
PP01 CRISPR/Cas9 mediated gene correction for the Wiskott-Aldrich syndrome
- You cannot add another "Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer" to your cart. View cart
Article: PP01 CRISPR/Cas9 mediated gene correction for the Wiskott-Aldrich syndrome
€3.03
Related products
-
Article: Highlights in squamous cell carcinoma of the head and neck
€3.03 Add to cart -
Article: INTRODUCTION
€3.03 Add to cart -
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€3.03 Add to cart -
Article: Highlights in gynaecological cancers
€3.03 Add to cart
Reviews
There are no reviews yet.